FDA批准也是**一个口服生长抑素类似物MYCAPSSA(奥曲肽)胶囊,治疗肢端肥大症

2020-06-27 MedSci原创 MedSci原创

“整个肢端肥大症人群一直都在等待口服疗法,FDA批准了第一种口服生长抑素类似物,将会对该类患者的生活产生重大影响。”

Chiasma公司宣布,美国食品药品监督管理局(FDA)批准其MYCAPSSA(奥曲肽,octreotide)胶囊,用于对奥曲肽或兰瑞肽治疗有效并耐受的肢端肥大症患者的长期维持治疗。MYCAPSSA是FDA批准的第一个也是唯一一个口服生长抑素类似物(SSA),也是FDA批准的第一个使用Chiasma的瞬时渗透性增强剂(TPE)技术的产品。

See the source image

肢端肥大症是一种罕见的慢性疾病,通常由垂体良性肿瘤引起,其特征是过量产生生长激素和胰岛素样生长因子-1激素,通常需要长期繁重的注射治疗。该公司估计,美国大约有8000名患者正在接受可注射的SSA疗法。

Acromegaly Community总裁Jill Sisco说:“肢端肥大症患者面临着许多与注射相关的挑战,需要新的治疗选择。整个肢端肥大症人群一直都在等待口服疗法,FDA批准了第一种口服SSA治疗,很可能对肢端肥大症患者及其护理人员的生活产生重大影响。”

CHIASMA OPTIMAL临床试验的主要研究者Susan Samson博士说:“关键的3期CHIASMA OPTIMAL试验数据显示,接受MYCAPSSA治疗的患者在实验结束时能够将平均IGF-1水平维持在正常范围内,我们相信口服奥曲肽胶囊该类患者具有重大意义,并且将解决长期尚未满足的治疗需求。”

原始出处:

https://www.firstwordpharma.com/node/1735926?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
    2021-02-24 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
    2020-11-12 clmlylxy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
    2020-12-19 bugit
  5. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]
    2020-06-29 guihongzh
  10. [GetPortalCommentsPageByObjectIdResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Feb 24 22:08:37 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690726, encodeId=c52a1690e26fe, content=<a href='/topic/show?id=3e05405353' target=_blank style='color:#2F92EE;'>#CAPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4053, encryptionId=3e05405353, topicName=CAPS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2129099925, createdName=clmlylxy, createdTime=Thu Nov 12 06:08:37 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664771, encodeId=f5b91664e71ea, content=<a href='/topic/show?id=65b5818609b' target=_blank style='color:#2F92EE;'>#肢端肥大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81860, encryptionId=65b5818609b, topicName=肢端肥大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cad25837873, createdName=654699882_84926994, createdTime=Wed Mar 24 14:08:37 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839839, encodeId=3d091839839fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 19 11:08:37 CST 2020, time=2020-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019189, encodeId=186e201918993, content=<a href='/topic/show?id=35516962114' target=_blank style='color:#2F92EE;'>#生长抑素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69621, encryptionId=35516962114, topicName=生长抑素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Fri Nov 06 05:08:37 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071109, encodeId=52fe20e110955, content=<a href='/topic/show?id=d96844552f4' target=_blank style='color:#2F92EE;'>#奥曲肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44552, encryptionId=d96844552f4, topicName=奥曲肽)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Thu Apr 15 13:08:37 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970234, encodeId=194519e02340a, content=<a href='/topic/show?id=b69b69624fe' target=_blank style='color:#2F92EE;'>#生长抑素类似物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69624, encryptionId=b69b69624fe, topicName=生长抑素类似物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Dec 24 07:08:37 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271197, encodeId=e99312e11978f, content=<a href='/topic/show?id=391f8186168' target=_blank style='color:#2F92EE;'>#肢端肥大症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81861, encryptionId=391f8186168, topicName=肢端肥大症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274832, encodeId=5be812e483232, content=<a href='/topic/show?id=1bbc12404ba' target=_blank style='color:#2F92EE;'>#MYC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12404, encryptionId=1bbc12404ba, topicName=MYC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482833, encodeId=73ce1482833d0, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Mon Jun 29 01:08:37 CST 2020, time=2020-06-29, status=1, ipAttribution=)]

相关资讯

JCEM:肢端肥大症患者的癌症发生率!

由此可见,在我们的研究中,肢端肥大症患者癌症的发病率略有增加,这是得到了23项研究的荟萃分析支持,虽然它也提示一些早期的研究存在选择偏倚。

JCEM:对肢端肥大症患者的生化控制能改善其胰岛素抵抗,但存在肥胖风险

肢端肥大症(acromegaly)是腺垂体分泌生长激素(GH)过多所致的体型和内脏器官异常肥大并伴有相应生理功能异常的一种内分泌与代谢性疾病。肢端肥大症还常与IGF-1(类胰岛素一号增长因子,也被称作“促生长因子”)的分泌过多有关。生长激素过多主要引起骨骼、软组织和内脏过渡增长,在青春期少年表现为巨人症(gigantism),在成年人则表现为肢端肥大症。来自美国的研究人员探讨了:与年龄、BMI、性

超声心动图诊断肢端肥大症心肌病1例

患者男,25岁。因“反复胸闷、气喘2个月余”入院。查体:血压148/81mmHg,头部巨颅,颧骨高耸,眉弓高突,唇肥厚,鼻唇沟隆起,鼻宽舌大,心尖搏动增强、弥散,心脏相对浊音界向左下扩大,心率110次/min,律齐。手脚粗大肥厚,皮肤粗厚,双下肢中度水肿。辅助检查:生长激素(GH)>40↑;泌乳素287.94ng/ml↑;脑利钠肽1471pg/ml↑。

NEJM:肢端肥大症相关的回状头皮-病例报道

头皮上的皮肤增厚和皱纹,称为回状头皮,可以作为孤立的症状出现,或者可能与许多疾病有关,例如肢端肥大症,如本例患者所示。

2019 KES立场声明:生长抑素类似物治疗肢端肥大症

2019年3月,韩国内分泌学会(KES)发布了生长抑素类似物治疗肢端肥大症的立场声明,文章主要内容包括肢端肥大症药物治疗中生长抑素类似物的特征、适应证、应用剂量,应用时间间隔、药物转换以及术前应用等内容。

肢端肥大症并发扩张性心肌病患者行前列腺粒子植入术的麻醉管理1例

患者,男,66岁,身高178 cm,体质量70kg,因“前列腺癌”入院。既往垂体瘤病史40余年(间断服用溴隐亭),扩张性心肌病病史7年,高血压病史7年,血压(BP)最高180/120mmHg,口服利血平、美托洛尔和贝那普利控制血压,平时BP控制在120/80mmHg左右,曾有心衰病史,经内科治疗好转,目前心功能Ⅱ级。27年前行右眼外伤手术,目前右眼失明。